Marizomib - Myeloma Experimental Treatment - Experimental Drugs


What is Marizomib?

Marizomib (NPI-0052) is a proteasome inhibitor being developed by Triphase Accelerator that is being evaluated in myeloma and other cancers. Marizomib is in the same class of agents as Velcade® (bortezomib), but it has a different structure. Proteasomes are enzymes found in cells and play an important role in regulating cell function and growth by controlling the breakdown of important proteins. Marizomib blocks the activity of proteasomes and by blocking the proteasome, it disrupts processes related to the growth and survival of cancer cells. Marizomib is given as an intravenous infusion.